<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152759</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-2506-001-CR</org_study_id>
    <nct_id>NCT04152759</nct_id>
  </id_info>
  <brief_title>Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blinded, Single-dose, 2-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2506 Injection vs Simponi in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Thera Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Thera Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized, double-blinded, single-dose, 2-arm parallel, comparative study to&#xD;
      evaluate the pharmacokinetics and safety of BAT2506 Injection vs Simponi in healthy chinese&#xD;
      male subjects A total of 182 subjects are planned to be included and randomized at a ratio of&#xD;
      1:1 to receive single subcutaneous administration of 50mg BAT2506 Injection or Simponi®&#xD;
      (EU-licensed ).&#xD;
&#xD;
      The study has a screening period of 14 days. PK blood samples will be collected from subjects&#xD;
      to determine the serum concentration of Golimumab, thus to evaluate the change and similarity&#xD;
      of the pharmacokinetics of the two study drugs.&#xD;
&#xD;
      The investigator will perform safety evaluation for vital signs, physical examinations,&#xD;
      injection site reaction, ECG, clinical laboratory tests and adverse events throughout the&#xD;
      study. Immunogenicity evaluation (ADA, ADA titration and nAb) will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Endpoint：AUC0-t</measure>
    <time_frame>0-71days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Endpoint：Cmax</measure>
    <time_frame>0-71days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Endpoint：AUC0-inf</measure>
    <time_frame>0-71days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>BAT2506 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg ；subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinponi(EU-licensed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg ；subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: BAT2506 injection Other Names: Simponi(EU-licensed)</intervention_name>
    <description>Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).&#xD;
Other Names:&#xD;
Simponi(EU-licensed)</description>
    <arm_group_label>BAT2506 injection</arm_group_label>
    <arm_group_label>Sinponi(EU-licensed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects aged18 and 50 years inclusive; BMI between 18 and 28 kg/m2 and&#xD;
             body weight between 50 and 80 kg.&#xD;
&#xD;
          -  Physical examinations and vital signs are normal or abnormal without clinical&#xD;
             significance.&#xD;
&#xD;
          -  Abdominal color Doppler ultrasound, laboratory tests, etc. are normal or abnormal&#xD;
             without clinical significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current or history of severe allergic reaction to foods or drugs and History of&#xD;
             allergy to study products.&#xD;
&#xD;
          -  Having severe injuries or surgery or fractures within 4 weeks before enrollment,or to&#xD;
             receive surgery during the study.&#xD;
&#xD;
          -  Having clinically significantclinical history abnormalities or other clinically&#xD;
             indicated diseases (including but not limited to gastrointestinal, renal, liver,&#xD;
             neurological, hematological, endocrine, tumor, lung, immune, mental or cardiovascular&#xD;
             diseases).&#xD;
&#xD;
          -  Having malignant tumor (excluding basal cell carcinoma who has undergone resection).&#xD;
&#xD;
          -  Having clinically significant chronic or acute infections at screening/incorporation;&#xD;
             or active infections,Includes acute and chronic infections as well as local infections&#xD;
             (bacteria, viruses, parasites, fungi or other opportunities) Sexually infected&#xD;
             pathogen).&#xD;
&#xD;
          -  Having a history of tuberculosis or latent tuberculosis or clinical manifestations&#xD;
             suspected of being tuberculosis(including But not limited to tuberculosis).&#xD;
&#xD;
          -  Having been exposed to tuberculosis or/and suspected tuberculosis symptoms and/or&#xD;
             signs within 3 months before screening.&#xD;
&#xD;
          -  Having used simponi,or any anti-tumor necrosis factor (TNF-α) biologic preparation or&#xD;
             any biological products within 6 months before enrollment or monoclonal antibodies&#xD;
             within a month.&#xD;
&#xD;
          -  Having used drugs within 30 days before enrollment (including but not limited to&#xD;
             prescription drugs, Chinese medicine, non-prescription drugs).&#xD;
&#xD;
          -  Having vaccinated active / attenuated vaccine within 12 weeks before screening or&#xD;
             planned to vaccinate active /attenuated vaccine the during the study.&#xD;
&#xD;
          -  Having a history of hypertension or systolic blood pressure ≥ 140 mmHg, or diastolic&#xD;
             blood pressure ≥ at screening/inclusion90 mmHg, and it is judged abnormalities with&#xD;
             clinical significance.&#xD;
&#xD;
          -  Electrocardiogram (ECG) examination abnormalities with clinical significance;&#xD;
&#xD;
          -  Having positive detection of golimumab anti-drug antibody (ADA) during screening.&#xD;
&#xD;
          -  Chest orthotopic examination abnormalities with clinical significance.&#xD;
&#xD;
          -  Tuberculosis enzyme-linked immunospot assay (T-SPOT. TB) positive test,&#xD;
&#xD;
          -  Having any alcoholic products within 24 hours prior to the use of the study drug.&#xD;
&#xD;
          -  A drug abuse test positive or a history of drug abuse over the past five years.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Bethune Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Golimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only one site study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

